Does the media prefer GHRS or RYTM?

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than GH Research. MarketBeat recorded 14 mentions for Rhythm Pharmaceuticals and 6 mentions for GH Research. Rhythm Pharmaceuticals' average media sentiment score of 1.18 beat GH Research's score of 0.47 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IBRX or GHRS?

In the previous week, ImmunityBio had 6 more articles in the media than GH Research. MarketBeat recorded 12 mentions for ImmunityBio and 6 mentions for GH Research. ImmunityBio's average media sentiment score of 0.57 beat GH Research's score of 0.47 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, COGT or GHRS?

GH Research is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A GH Research N/A N/A -$48.26M -$0.92 N/A

Is COGT or GHRS more profitable?

GH Research's return on equity of -19.36% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% GH Research N/A -19.36% -18.73%

Does the media refer more to COGT or GHRS?

In the previous week, Cogent Biosciences had 3 more articles in the media than GH Research. MarketBeat recorded 9 mentions for Cogent Biosciences and 6 mentions for GH Research. Cogent Biosciences' average media sentiment score of 1.53 beat GH Research's score of 0.47 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive GH Research 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GHRS or MIRM?

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than GH Research. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 6 mentions for GH Research. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat GH Research's score of 0.47 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, LNTH or GHRS?

Lantheus has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.21 $233.56M $4.15 24.01 GH Research N/A N/A -$48.26M -$0.92 N/A

Is LNTH or GHRS more profitable?

Lantheus has a net margin of 18.05% compared to GH Research's net margin of 0.00%. Lantheus' return on equity of 29.32% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% GH Research N/A -19.36% -18.73%

Does the media favor LNTH or GHRS?

In the previous week, Lantheus had 8 more articles in the media than GH Research. MarketBeat recorded 14 mentions for Lantheus and 6 mentions for GH Research. GH Research's average media sentiment score of 0.47 beat Lantheus' score of 0.33 indicating that GH Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral GH Research 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

GH Research (GHRS) Competitors

$28.07 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$27.87 -0.20 (-0.70%)

As of 07/31/2026 07:36 PM Eastern

Compare

GHRS vs. RYTM, IBRX, COGT, MIRM, and LNTH

Should you buy GH Research stock or one of its competitors? MarketBeat compares GH Research with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GH Research include Rhythm Pharmaceuticals (RYTM), ImmunityBio (IBRX), Cogent Biosciences (COGT), Mirum Pharmaceuticals (MIRM), and Lantheus (LNTH).

How does GH Research compare to Rhythm Pharmaceuticals?

GH Research (NASDAQ:GHRS) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

GH Research has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

GH Research presently has a consensus target price of $40.78, indicating a potential upside of 45.27%. Rhythm Pharmaceuticals has a consensus target price of $138.73, indicating a potential upside of 39.78%. Given GH Research's higher possible upside, research analysts plainly believe GH Research is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

GH Research has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. GH Research's return on equity of -19.36% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

GH Research has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Rhythm Pharmaceuticals	$189.76M	35.84	-$196.54M	-$3.13	N/A

56.9% of GH Research shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than GH Research. MarketBeat recorded 14 mentions for Rhythm Pharmaceuticals and 6 mentions for GH Research. Rhythm Pharmaceuticals' average media sentiment score of 1.18 beat GH Research's score of 0.47 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GH Research beats Rhythm Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does GH Research compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

GH Research has lower revenue, but higher earnings than ImmunityBio. GH Research is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	66.29	-$351.40M	-$0.85	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

GH Research has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
GH Research	N/A	-19.36%	-18.73%

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ImmunityBio presently has a consensus target price of $14.20, suggesting a potential upside of 98.05%. GH Research has a consensus target price of $40.78, suggesting a potential upside of 45.27%. Given ImmunityBio's stronger consensus rating and higher possible upside, equities research analysts plainly believe ImmunityBio is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
GH Research	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, ImmunityBio had 6 more articles in the media than GH Research. MarketBeat recorded 12 mentions for ImmunityBio and 6 mentions for GH Research. ImmunityBio's average media sentiment score of 0.57 beat GH Research's score of 0.47 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GH Research	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market. Comparatively, GH Research has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Summary

ImmunityBio beats GH Research on 9 of the 15 factors compared between the two stocks.

How does GH Research compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Cogent Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, GH Research has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

In the previous week, Cogent Biosciences had 3 more articles in the media than GH Research. MarketBeat recorded 9 mentions for Cogent Biosciences and 6 mentions for GH Research. Cogent Biosciences' average media sentiment score of 1.53 beat GH Research's score of 0.47 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
GH Research	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

56.9% of GH Research shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GH Research's return on equity of -19.36% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
GH Research	N/A	-19.36%	-18.73%

Cogent Biosciences presently has a consensus price target of $45.90, indicating a potential upside of 17.90%. GH Research has a consensus price target of $40.78, indicating a potential upside of 45.27%. Given GH Research's higher probable upside, analysts clearly believe GH Research is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
GH Research	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67

GH Research is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

Summary

GH Research beats Cogent Biosciences on 8 of the 14 factors compared between the two stocks.

How does GH Research compare to Mirum Pharmaceuticals?

GH Research (NASDAQ:GHRS) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

56.9% of GH Research shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Mirum Pharmaceuticals has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Mirum Pharmaceuticals	$569.61M	11.34	-$23.36M	-$13.61	N/A

GH Research has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

GH Research currently has a consensus target price of $40.78, indicating a potential upside of 45.27%. Mirum Pharmaceuticals has a consensus target price of $143.40, indicating a potential upside of 35.35%. Given GH Research's higher possible upside, research analysts clearly believe GH Research is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

GH Research has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than GH Research. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 6 mentions for GH Research. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat GH Research's score of 0.47 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mirum Pharmaceuticals beats GH Research on 11 of the 16 factors compared between the two stocks.

How does GH Research compare to Lantheus?

Lantheus (NASDAQ:LNTH) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Lantheus presently has a consensus target price of $109.71, suggesting a potential upside of 10.11%. GH Research has a consensus target price of $40.78, suggesting a potential upside of 45.27%. Given GH Research's higher possible upside, analysts clearly believe GH Research is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
GH Research	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67

Lantheus has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.21	$233.56M	$4.15	24.01
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

In the previous week, Lantheus had 8 more articles in the media than GH Research. MarketBeat recorded 14 mentions for Lantheus and 6 mentions for GH Research. GH Research's average media sentiment score of 0.47 beat Lantheus' score of 0.33 indicating that GH Research is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
GH Research	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Lantheus shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, GH Research has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Lantheus has a net margin of 18.05% compared to GH Research's net margin of 0.00%. Lantheus' return on equity of 29.32% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
GH Research	N/A	-19.36%	-18.73%

Summary

Lantheus beats GH Research on 10 of the 14 factors compared between the two stocks.

Get GH Research News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GHRS vs. The Competition

Export

Metric	GH Research	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.93B	$11.71B	$6.85B	$12.42B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-30.51	799.05	282.30	24.66
Price / Sales	N/A	748.51	563.12	75.93
Price / Cash	N/A	14.82	28.60	46.71
Price / Book	6.22	10.28	10.96	6.07
Net Income	-$48.26M	$2.82B	$3.49B	$347.99M
7 Day Performance	1.15%	-0.16%	-0.64%	-0.44%
1 Month Performance	3.92%	-4.00%	-5.23%	-4.81%
1 Year Performance	104.29%	156.08%	61.97%	18.61%

GH Research Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GHRS GH Research	2.1795 of 5 stars	$28.07 flat	$40.78 +45.3%	+104.3%	$1.93B	N/A	N/A	10	Upcoming Earnings
RYTM Rhythm Pharmaceuticals	3.4024 of 5 stars	$106.91 +0.7%	$138.73 +29.8%	+12.4%	$7.33B	$189.76M	N/A	140	Positive News Upcoming Earnings Gap Up
IBRX ImmunityBio	2.5511 of 5 stars	$6.87 -1.8%	$14.20 +106.8%	+202.5%	$7.19B	$140.98M	N/A	590	Upcoming Earnings Gap Up
COGT Cogent Biosciences	2.1996 of 5 stars	$39.67 -1.9%	$45.90 +15.7%	+241.5%	$6.79B	N/A	N/A	80	Positive News Upcoming Earnings Gap Up
MIRM Mirum Pharmaceuticals	3.3465 of 5 stars	$111.29 -2.6%	$143.40 +28.9%	+103.7%	$6.77B	$569.61M	N/A	140	Positive News Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GHRS) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GH Research (GHRS) Competitors

GHRS vs. RYTM, IBRX, COGT, MIRM, and LNTH

How does GH Research compare to Rhythm Pharmaceuticals?

Summary

How does GH Research compare to ImmunityBio?

Summary

How does GH Research compare to Cogent Biosciences?

Summary

How does GH Research compare to Mirum Pharmaceuticals?

Summary

How does GH Research compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GH Research (GHRS) Competitors

GHRS vs. RYTM, IBRX, COGT, MIRM, and LNTH

How does GH Research compare to Rhythm Pharmaceuticals?

Which has more volatility & risk, GHRS or RYTM?

Do analysts rate GHRS or RYTM?

Is GHRS or RYTM more profitable?

Which has stronger earnings and valuation, GHRS or RYTM?

Do institutionals & insiders believe in GHRS or RYTM?

Does the media prefer GHRS or RYTM?

Summary

How does GH Research compare to ImmunityBio?

Which has preferable valuation and earnings, IBRX or GHRS?

Is IBRX or GHRS more profitable?

Do insiders & institutionals believe in IBRX or GHRS?

Do analysts rate IBRX or GHRS?

Does the media favor IBRX or GHRS?

Which has more risk and volatility, IBRX or GHRS?

Summary

How does GH Research compare to Cogent Biosciences?

Which has more volatility & risk, COGT or GHRS?

Does the media refer more to COGT or GHRS?

Do insiders and institutionals believe in COGT or GHRS?

Is COGT or GHRS more profitable?

Do analysts prefer COGT or GHRS?

Which has better earnings and valuation, COGT or GHRS?

Summary

How does GH Research compare to Mirum Pharmaceuticals?

Do insiders and institutionals believe in GHRS or MIRM?

Which has preferable earnings & valuation, GHRS or MIRM?

Is GHRS or MIRM more profitable?

Do analysts rate GHRS or MIRM?

Which has more risk & volatility, GHRS or MIRM?

Does the media prefer GHRS or MIRM?

Summary

How does GH Research compare to Lantheus?

Do analysts rate LNTH or GHRS?

Which has stronger earnings & valuation, LNTH or GHRS?

Does the media favor LNTH or GHRS?

Do insiders & institutionals hold more shares of LNTH or GHRS?

Which has more risk and volatility, LNTH or GHRS?

Is LNTH or GHRS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools